Your browser doesn't support javascript.
loading
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.
Murhekar, Manoj V; Bhatnagar, Tarun; Selvaraju, Sriram; Rade, Kiran; Saravanakumar, V; Vivian Thangaraj, Jeromie Wesley; Kumar, Muthusamy Santhosh; Shah, Naman; Sabarinathan, R; Turuk, Alka; Anand, Parveen Kumar; Asthana, Smita; Balachandar, Rakesh; Bangar, Sampada Dipak; Bansal, Avi Kumar; Bhat, Jyothi; Chakraborty, Debjit; Rangaraju, Chethana; Chopra, Vishal; Das, Dasarathi; Deb, Alok Kumar; Devi, Kangjam Rekha; Dwivedi, Gaurav Raj; Salim Khan, S Muhammad; Haq, Inaamul; Kumar, M Sunil; Laxmaiah, Avula; Mahapatra, Amarendra; Mitra, Anindya; Nirmala, A R; Pagdhune, Avinash; Qurieshi, Mariya Amin; Ramarao, Tekumalla; Sahay, Seema; Sharma, Y K; Shrinivasa, Marinaik Basavegowdanadoddi; Shukla, Vijay Kumar; Singh, Prashant Kumar; Viramgami, Ankit; Wilson, Vimith Cheruvathoor; Yadav, Rajiv; Girish Kumar, C P; Luke, Hanna Elizabeth; Ranganathan, Uma Devi; Babu, Subash; Sekar, Krithikaa; Yadav, Pragya D; Sapkal, Gajanan N; Das, Aparup; Das, Pradeep.
Afiliação
  • Murhekar MV; ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
  • Bhatnagar T; ICMR School of Public Health, Chennai, Tamil Nadu, India.
  • Selvaraju S; Divisions of Epidemiology, Chennai, Tamil Nadu, India.
  • Rade K; WHO Country Office for India, New Delhi, India.
  • Saravanakumar V; Division of Epidemiology, Chennai, Tamil Nadu, India.
  • Vivian Thangaraj JW; ICMR School of Public Health, Chennai, Tamil Nadu, India.
  • Kumar MS; ICMR School of Public Health, Chennai, Tamil Nadu, India.
  • Shah N; Jan Swasthya Sahyog, Bilaspur, India.
  • Sabarinathan R; Division of Epidemiology, Chennai, Tamil Nadu, India.
  • Turuk A; Division of Epidemiology & Communicable Diseases, All India Institute of Medical Sciences, New Delhi, India.
  • Anand PK; Division of Bio-Statistics, Jodhpur, Rajasthan, India.
  • Asthana S; Divisions of Epidemiology & Biostatistics, Noida, India.
  • Balachandar R; Division of Clinical Epidemiology, Ahmedabad, Gujarat, India.
  • Bangar SD; Divisions of Epidemiology & Biostatistics, Pune, Maharashtra, India.
  • Bansal AK; Division of Epidemiology, Agra, India.
  • Bhat J; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
  • Chakraborty D; Division of Epidemiology, ICMR-National Institute of Cholera & Enteric Diseases, Kolkata, West Bengal, India.
  • Rangaraju C; Division of Advocacy, Communication & Social Mobilisation, Bengaluru, Karnataka, India.
  • Chopra V; State TB Training & Demonstration Centre, Patiala, Punjab, India.
  • Das D; ICMRRegional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Deb AK; Division of Epidemiology, ICMR-National Institute of Cholera & Enteric Diseases, Kolkata, West Bengal, India.
  • Devi KR; Division of Enteric Diseases, ICMR-Regional Medical Research Centre, Northeast Region, Dibrugarh, Assam, India.
  • Dwivedi GR; ICMR-Regional Medical Research Centre, Gorakhpur, India.
  • Salim Khan SM; Department of Community Medicine, Government Medical College, Srinagar, Jammu & Kashmir, India.
  • Haq I; Department of Community Medicine, Government Medical College, Srinagar, Jammu & Kashmir, India.
  • Kumar MS; State TB Training & Demonstration Centre, Thiruvananthapuram, Kerala, India.
  • Laxmaiah A; Division of Public Health Nutrition, ICMRNational Institute of Nutrition, Hyderabad, Telangana, India.
  • Madhuka; Division of Clinical Medicine, ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India.
  • Mahapatra A; ICMRRegional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Mitra A; State TB Training & Demonstration Centre, Ranchi, Jharkhand, India.
  • Nirmala AR; Lady Willingdon State TB Centre, Government of Karnataka, Bengaluru, Karnataka, India.
  • Pagdhune A; Division of Clinical Epidemiology, ICMR-National Institute of Occupational Health, Ahmedabad, Gujarat, India.
  • Qurieshi MA; Department of Community Medicine, Government Medical College, Srinagar, Jammu & Kashmir, India.
  • Ramarao T; State TB Cell, Vijayawada, Andhra Pradesh, India.
  • Sahay S; Social and Behavioural Research Sciences, Pune, Maharashtra, India.
  • Sharma YK; Directorate Health Services, Raipur, Chhattisgarh, India.
  • Shrinivasa MB; Clinical Research, Chennai, Tamil Nadu, India.
  • Shukla VK; Directorate Health Services, Raipur, Chhattisgarh, India.
  • Singh PK; Preventive Oncology, ICMR-National Institute of Cancer Prevention & Research, Noida, India.
  • Viramgami A; Division of Clinical Epidemiology, ICMR-National Institute of Occupational Health, Ahmedabad, Gujarat, India.
  • Wilson VC; Divisions of Epidemiology, Chennai, Tamil Nadu, India.
  • Yadav R; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
  • Girish Kumar CP; Laboratory Division, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
  • Luke HE; HIV/AIDS, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • Ranganathan UD; Immunology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • Babu S; NIH-ICER (International Centers for Excellence in Research) Program, Chennai, India.
  • Sekar K; Divisions of Epidemiology, Chennai, Tamil Nadu, India.
  • Yadav PD; Maximum Containment Laboratory, Pune, Maharashtra, India.
  • Sapkal GN; Diagnostic Virology Group, ICMR-National Institute of Virology, Pune, Maharashtra, India.
  • Das A; ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Indian J Med Res ; 152(1 & 2): 48-60, 2020.
Article em En | MEDLINE | ID: mdl-32952144
BACKGROUND & OBJECTIVES: Population-based seroepidemiological studies measure the extent of SARS-CoV-2 infection in a country. We report the findings of the first round of a national serosurvey, conducted to estimate the seroprevalence of SARS-CoV-2 infection among adult population of India. METHODS: From May 11 to June 4, 2020, a randomly sampled, community-based survey was conducted in 700 villages/wards, selected from the 70 districts of the 21 States of India, categorized into four strata based on the incidence of reported COVID-19 cases. Four hundred adults per district were enrolled from 10 clusters with one adult per household. Serum samples were tested for IgG antibodies using COVID Kavach ELISA kit. All positive serum samples were re-tested using Euroimmun SARS-CoV-2 ELISA. Adjusting for survey design and serial test performance, weighted seroprevalence, number of infections, infection to case ratio (ICR) and infection fatality ratio (IFR) were calculated. Logistic regression was used to determine the factors associated with IgG positivity. RESULTS: Total of 30,283 households were visited and 28,000 individuals were enrolled. Population-weighted seroprevalence after adjusting for test performance was 0.73 per cent [95% confidence interval (CI): 0.34-1.13]. Males, living in urban slums and occupation with high risk of exposure to potentially infected persons were associated with seropositivity. A cumulative 6,468,388 adult infections (95% CI: 3,829,029-11,199,423) were estimated in India by the early May. The overall ICR was between 81.6 (95% CI: 48.3-141.4) and 130.1 (95% CI: 77.0-225.2) with May 11 and May 3, 2020 as plausible reference points for reported cases. The IFR in the surveyed districts from high stratum, where death reporting was more robust, was 11.72 (95% CI: 7.21-19.19) to 15.04 (9.26-24.62) per 10,000 adults, using May 24 and June 1, 2020 as plausible reference points for reported deaths. INTERPRETATION & CONCLUSIONS: Seroprevalence of SARS-CoV-2 was low among the adult population in India around the beginning of May 2020. Further national and local serosurveys are recommended to better inform the public health strategy for containment and mitigation of the epidemic in various parts of the country.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Imunoglobulina G / Infecções por Coronavirus / Betacoronavirus / Anticorpos Antivirais Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Imunoglobulina G / Infecções por Coronavirus / Betacoronavirus / Anticorpos Antivirais Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article